A phase I trial of the γ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).

被引：3
|
作者：
Cook, Natalie
Basu, Bristi
Smith, Donna-Michelle
Gopinathan, Aarthi
Evans, Thomas Jeff
Steward, William P.
Hagemann, Thorsten
Venugopal, Balaji
Tuveson, David A.
Hategan, Mirela
Anthoney, David Alan
Farmer, Hayley
Turner, Helen
McLeod, Robert
Halford, Sarah E. R.
Jodrell, Duncan Ian
机构：
[1] Univ Cambridge, Cambridge Res Inst, Canc Res UK, Cambridge, England
[2] Cambridge Univ NHS Fdn Trust, Addenbrookes Hosp, Dept Oncol, Cambridge, England
[3] Univ Cambridge, Cambridge Inst, Canc Res UK, Cambridge, England
[4] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[5] Univ Leicester, Dept Oncol, Leicester, Leics, England
[6] Univ London, Barts Canc Inst, London, England
[7] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Cold Spring Harbor Labs, New York, NY USA
[9] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[10] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[11] Canc Res UK, Drug Dev Off, London, England
[12] Canc Res UK, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4116
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
    Natalie Cook
    Bristi Basu
    Donna-Michelle Smith
    Aarthi Gopinathan
    Jeffry Evans
    William P Steward
    Daniel Palmer
    David Propper
    Balaji Venugopal
    Mirela Hategan
    D Alan Anthoney
    Lisa V Hampson
    Michael Nebozhyn
    David Tuveson
    Hayley Farmer-Hall
    Helen Turner
    Robert McLeod
    Sarah Halford
    Duncan Jodrell
    British Journal of Cancer, 2018, 118 : 793 - 801
  • [2] A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
    Cook, Natalie
    Basu, Bristi
    Smith, Donna-Michelle
    Gopinathan, Aarthi
    Evans, Jeffry
    Steward, William P.
    Palmer, Daniel
    Propper, David
    Venugopal, Balaji
    Hategan, Mirela
    Anthoney, D. Alan
    Hampson, Lisa V.
    Nebozhyn, Michael
    Tuveson, David
    Farmer-Hall, Hayley
    Turner, Helen
    McLeod, Robert
    Halford, Sarah
    Jodrell, Duncan
    BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 793 - 801
  • [3] Phase lb Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer
    Schott, A. F.
    Chang, J. C.
    Krop, I. E.
    Griffith, K. A.
    Layman, R. M.
    Hayes, D. F.
    Wicha, M. S.
    CANCER RESEARCH, 2010, 70
  • [4] Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752
    Chen, XiuXiu
    Gong, LiHua
    Ou, RongYing
    Zheng, ZhenZhen
    Chen, JinYan
    Xie, FengFeng
    Huang, XiaoXiu
    Qiu, JianGe
    Zhang, WenJi
    Jiang, QiWei
    Yang, Yang
    Zhu, Hua
    Shi, Zhi
    Yan, XiaoJian
    GYNECOLOGIC ONCOLOGY, 2016, 140 (03) : 537 - 544
  • [5] Phase I study of the Gamma Secretase Inhibitor MK-0752 in patients with metastatic breast and other advanced solid tumors
    LoRusso, Patricia
    Demuth, Tim
    Heath, Elisabeth
    Malburg, Lisa
    Pilat, Mary Jo
    Kesari, Santosh
    Russak, Jason
    Knowles, James
    Beckman, Robert
    Fang, Lanyan
    Stone, Julie
    Krop, Ian
    CANCER RESEARCH, 2009, 69
  • [6] Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
    Krop, Ian
    Demuth, Tim
    Guthrie, Tina
    Wen, Patrick Y.
    Mason, Warren P.
    Chinnaiyan, Prakash
    Butowski, Nicholas
    Groves, Morris D.
    Kesari, Santosh
    Freedman, Steven J.
    Blackman, Samuel
    Watters, James
    Loboda, Andrey
    Podtelezhnikov, Alexei
    Lunceford, Jared
    Chen, Cong
    Giannotti, Maxine
    Hing, Jeremy
    Beckman, Robert
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) : 2307 - 2313
  • [7] Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Munster, Pamela N.
    Hollehecque, Antoine
    Argiles, Guillem
    Dajanl, Olav
    Cheng, Jonathan D.
    Wang, Ruixue
    Swift, Ann M.
    Tosolini, Alessandra
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours
    Piha-Paul, S. A.
    Munster, P. N.
    Hollebecque, A.
    Argiles, G.
    Dajani, O.
    Cheng, J. D.
    Wang, R.
    Swift, A.
    Tosolini, A.
    Gupta, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (14) : 1865 - 1873
  • [9] Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nabpaclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC).
    Turk, Anita Ahmed
    Helft, Paul R.
    Sehdev, Amikar
    Shahda, Safi
    Loehrer, Patrick J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 731 - 731
  • [10] Phase I pharmacokinetic, and pharmacodynamic trial of the novel oral notch inhibitor MK-0752 in patients with advanced breast cancer and other solid tumors.
    Krop, I. E.
    Kosh, M.
    Fearen, I
    Savoie, J.
    Dallob, A.
    Stone, J.
    Winer, E.
    Freedman, S. J.
    LoRusso, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S287 - S287
12345